GlassScriptPhysician profile
Nhung D Tran
NPI 1386675775
$9,062.42
in general payments reported to CMS, 2019-2025
35 companies · $2,797 in 2025
The $2,797 reported for 2025 was more than what 95% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $598 · 2022: $1,553 · 2023: $1,848 · 2024: $2,267 · 2025: $2,797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,901 · Education: $10.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,901.22 |
| Education | $10.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,698.99 | 2021-2025 | |
| Janssen Biotech, INC. | $1,338.54 | 2021-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,262.83 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,021.30 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Ardelyx, INC. | $497.49 | 2022-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $360.26 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $271.28 | 2021-2025 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $250.41 | 2022-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $210.29 | 2022-2025 | Linzess |
| Pfizer INC. | $188.95 | 2021-2025 | |
| Genzyme Corporation | $180.02 | 2023-2025 | |
| Lilly USA, LLC | $151.51 | 2023-2025 | Omvoh |
| Celgene Corporation | $140.81 | 2021-2023 | Zeposia |
| Ferring Pharmaceuticals INC. | $136.80 | 2023-2024 | Rebyota |
| Madrigal Pharmaceuticals | $117.94 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $101.43 | 2021-2024 | Suflave, Sutab |
| Sandoz INC. | $99.94 | 2023-2025 | Hyrimoz |
| Exact Sciences Corporation | $89.26 | 2024-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $86.03 | 2025 | Wegovy |
| Qol Medical, LLC | $84.43 | 2022-2023 | Sucraid |
| Alnylam Pharmaceuticals INC. | $83.22 | 2023-2025 | Givlaari, Onpattro |
| Organon LLC | $81.30 | 2023-2024 | Renflexis, Hadlima |
| Ipsen Biopharmaceuticals, INC | $79.74 | 2025 | Iqirvo |
| Amgen INC. | $77.29 | 2022-2023 | Amjevita, Avsola |
| Daiichi Sankyo INC. | $74.46 | 2022-2023 | Injectafer |
| Sight Sciences, INC. | $71.70 | 2021 | |
| Merck Sharp & Dohme LLC | $58.01 | 2023-2024 | Dificid |
| Blueprint Medicines Corporation | $52.04 | 2023-2025 | Ayvakit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.85 | 2023 | Cyltezo |
| Nestle Healthcare Nutrition INC. | $39.55 | 2022-2023 | |
| Gilead Sciences, INC. | $35.64 | 2022-2024 | |
| Celltrion USA INC. | $27.18 | 2024 | Zymfentra |
| Pharmacosmos Therapeutics INC. | $24.67 | 2025 | Monoferric |
| Fresenius Kabi USA, LLC | $17.78 | 2024 | Idacio |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nhung Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.